ESSA Pharma Inc
NASDAQ:EPIX

Watchlist Manager
ESSA Pharma Inc Logo
ESSA Pharma Inc
NASDAQ:EPIX
Watchlist
Price: 1.61 USD -1.23% Market Closed
Market Cap: 71.5m USD
Have any thoughts about
ESSA Pharma Inc?
Write Note

Net Margin
ESSA Pharma Inc

0%
Current
0%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
-28.5m
/
Revenue
0

Net Margin Across Competitors

Country Company Market Cap Net
Margin
CA
ESSA Pharma Inc
NASDAQ:EPIX
71.5m USD N/A
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
316.5B USD
9%
US
Amgen Inc
NASDAQ:AMGN
141.2B USD
13%
US
Gilead Sciences Inc
NASDAQ:GILD
117.1B USD
0%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.3B USD
-5%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
135.7B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.2B USD
34%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36B EUR
-14%
Country CA
Market Cap 71.5m USD
Net Margin N/A
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 316.5B USD
Net Margin
9%
Country US
Market Cap 141.2B USD
Net Margin
13%
Country US
Market Cap 117.1B USD
Net Margin
0%
Country US
Market Cap 105.3B USD
Net Margin
-5%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 135.7B AUD
Net Margin
18%
Country US
Market Cap 78.2B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 36B EUR
Net Margin
-14%
No Stocks Found

ESSA Pharma Inc
Glance View

Market Cap
71.5m USD
Industry
Biotechnology

ESSA Pharma, Inc. is a clinical stage pharmaceutical company. The company is headquartered in Vancouver, British Columbia and currently employs 30 full-time employees. The firm is focused on developing therapies for the treatment of prostate cancer. The Company’s lead candidate, EPI-7386 is an oral, small molecule that inhibits the androgen receptor (AR) through a novel mechanism of action (N-terminal domain inhibition). The firm is evaluating EPI-7386 as a monotherapy for the treatment of adult male patients with metastatic castration-resistant prostate cancer (mCRPC) resistant to standard-of-care treatments.

EPIX Intrinsic Value
8.86 USD
Undervaluation 82%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
-28.5m
/
Revenue
0
What is the Net Margin of ESSA Pharma Inc?

Based on ESSA Pharma Inc's most recent financial statements, the company has Net Margin of 0%.